全文获取类型
收费全文 | 23016篇 |
免费 | 1452篇 |
国内免费 | 177篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 688篇 |
妇产科学 | 609篇 |
基础医学 | 1917篇 |
口腔科学 | 139篇 |
临床医学 | 2221篇 |
内科学 | 10862篇 |
皮肤病学 | 120篇 |
神经病学 | 765篇 |
特种医学 | 280篇 |
外科学 | 3108篇 |
综合类 | 770篇 |
现状与发展 | 3篇 |
一般理论 | 2篇 |
预防医学 | 1490篇 |
眼科学 | 132篇 |
药学 | 814篇 |
3篇 | |
中国医学 | 57篇 |
肿瘤学 | 594篇 |
出版年
2023年 | 902篇 |
2022年 | 1210篇 |
2021年 | 1554篇 |
2020年 | 1255篇 |
2019年 | 740篇 |
2018年 | 1051篇 |
2017年 | 999篇 |
2016年 | 957篇 |
2015年 | 863篇 |
2014年 | 1738篇 |
2013年 | 1270篇 |
2012年 | 1279篇 |
2011年 | 1234篇 |
2010年 | 1104篇 |
2009年 | 1126篇 |
2008年 | 851篇 |
2007年 | 908篇 |
2006年 | 829篇 |
2005年 | 737篇 |
2004年 | 651篇 |
2003年 | 556篇 |
2002年 | 476篇 |
2001年 | 446篇 |
2000年 | 301篇 |
1999年 | 271篇 |
1998年 | 143篇 |
1997年 | 86篇 |
1996年 | 85篇 |
1995年 | 57篇 |
1994年 | 72篇 |
1993年 | 42篇 |
1992年 | 95篇 |
1991年 | 58篇 |
1990年 | 57篇 |
1989年 | 52篇 |
1988年 | 37篇 |
1987年 | 30篇 |
1986年 | 41篇 |
1985年 | 36篇 |
1984年 | 36篇 |
1983年 | 39篇 |
1982年 | 49篇 |
1981年 | 45篇 |
1980年 | 42篇 |
1979年 | 41篇 |
1978年 | 29篇 |
1977年 | 35篇 |
1976年 | 26篇 |
1975年 | 23篇 |
1973年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
1.
2.
《Mayo Clinic proceedings. Mayo Clinic》2022,97(10):1942-1946
3.
4.
5.
《Clinical therapeutics》2022,44(7):1012-1025
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are the mainstay of treatment for hypercholesterolemia as they effectively reduce LDL-C levels and risk of atherosclerotic cardiovascular disease. Apart from hyperglycemia, dyslipidemia and HDL dysfunction are known risk factors for neuropathy in people with obesity and diabetes. Although there are case reports of statin-induced neuropathy, ad hoc analyses of clinical trials and observational studies have shown that statins may improve peripheral neuropathy. However, large randomized controlled trials and meta-analyses of cardiovascular outcome trials with statins and other lipid-lowering drugs have not reported on neuropathy outcomes. Because neuropathy was not a prespecified outcome in major cardiovascular trials, one cannot conclude whether statins or other lipid-lowering therapies increase or decrease the risk of neuropathy. The aim of this review was to assess if statins have beneficial or detrimental effects on neuropathy and whether there is a need for large well-powered interventional studies using objective neuropathy end points. 相似文献
6.
《Journal of clinical lipidology》2022,16(2):115-127
Metabolic risk for cardiovascular and other systems includes much more than just LDL cholesterol. This JCL Roundtable brings together 3 experts to address new opportunities to reduce the risks posed by obesity, diabetes, and fatty liver disease. Successful nutritional approaches to weight loss are diverse and need to be matched with individual preferences. Topiramate plus extended-release phentermine has been shown to promote meaningful weight loss in randomized trials, but the patented drug combination is expensive. Clinical experience suggests that generic topiramate and phentermine may also be effective. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown favorable tolerability and efficacy for cardiovascular disease in randomized trials, an achievement without precedent among earlier diabetes medications. These 2 drug classes differ in their effects. GLP-1 RAs decrease atherosclerotic cardiovascular events and also decrease hemoglobin A1c, body weight, blood pressure, and possibly diabetic renal disease. SGLT2 inhibitors are effective in reducing heart failure events even among nondiabetic patients. They also decrease progression of diabetic renal disease. The presence of nonalcoholic fatty liver disease signifies risk for atherosclerotic cardiovascular disease as well as cirrhosis and serious hepatic decompensation, including hepatocellular carcinoma. The key to identifying cirrhosis risk is to assess pre-emptively liver fibrosis, which can be predicted initially with blood test risk scores (e.g., FIB-4 index) and more definitively by transient elastography and other imaging techniques and/or liver biopsy. Some medications approved for the treatment of type 2 diabetes may reduce liver fat (SGLT2 inhibitors, insulin) or even reverse steatohepatitis in paired liver biopsy studies (GLP-1 RAs or pioglitazone) Overall the field of preventive metabolic medicine is expanding. Clinical lipidologists should become familiar with recent advances. 相似文献
7.
8.
9.
10.
《Journal of diabetes and its complications》2022,36(8):108260
AimTo verify whether arterial stiffness and endothelial dysfunction influence lower limb muscle strength and gait speed in older adults with type 2 diabetes mellitus (T2DM).MethodsCross-sectional study including seventy-eight older adults with T2DM (aged 67 ± 6 years and 42 % male). Arterial stiffness was assessed using pulse wave velocity (PWV), while endothelial function was measured by flow-mediated dilation (FMD). Lower limb muscle strength and gait speed were assessed using the 30-second chair stand test (30s-CST) and 10-Meter Walk Test, respectively.ResultsBoth PWV (m/s) and FMD (%) were univariately associated with number of repetitions in 30s-CST and gait speed (P < 0.05). After control for age, sex and body mass index, PWV remained associated with repetitions in 30s-CST (95 % CI: ?0.494 to ?0.054; P = 0.015) and gait speed (95 % CI: ?0.039 to ?0.002; P = 0.031). After adjustments for control variables, T2DM duration and glycemic control, FMD was associated with repetitions in 30s-CST (95 % CI: 0.008 to 0.324; P = 0.039) and gait speed (95 % CI: 0.011 to 0.038; P = 0.001).ConclusionIn older adults with T2DM, both arterial stiffness and endothelial dysfunction are associated with decreased leg muscle strength and slower gait speed. 相似文献